# A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors

> **NCT05716295** · PHASE1,PHASE2 · TERMINATED · sponsor: **Medikine, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** MDK-703
- **DRUG:** Checkpoint Inhibitor, Immune

## Key facts

- **NCT ID:** NCT05716295
- **Lead sponsor:** Medikine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-02-08
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Corporate decision
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05716295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05716295, "A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05716295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*